Diabetes type 1 vaccine oral - Diamyd Therapeutics

Drug Profile

Diabetes type 1 vaccine oral - Diamyd Therapeutics

Alternative Names: Oramyd

Latest Information Update: 21 Feb 2013

Price : $50

At a glance

  • Originator Diamyd Therapeutics; GTC Biotherapeutics
  • Developer Diamyd Therapeutics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
  • 15 Oct 2002 Suspended - Preclinical for Type-1 diabetes mellitus in Sweden (PO)
  • 19 Jun 2002 Genzyme Transgenics Corporation is now called GTC Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top